CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers
TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.
OLED display producers rely heavily on deuterated benzene (benzene-d6) as a critical starting material in their synthesis processes. However, this results in significant quantities of depleted benzene-d6, which is no longer usable but still retains considerable deuterium value. The disposal of such depleted material poses environmental challenges and substantial expenses.
CIL's benzene-recovery program offers a transformative solution. Customers can now return their depleted benzene-d6 to CIL, where it undergoes a proprietary re-enrichment process to restore it to virgin material quality. This service is available at a significant cost savings compared to new benzene-d6, providing significant economic benefits.
Beyond the financial advantages, the program has far-reaching environmental and supply implications. It eliminates the need for costly disposal, reduces the demand on increasingly scarce deuterium (derived from heavy water, D2O) and conserves this vital resource for its growing applications in science, medical diagnostics, pharmaceuticals, and semiconductor production.
Recycling offers several sustainable benefits. It reduces pollution by releasing fewer chemicals into the environment. Recycling also saves energy, as reprocessing chemicals like benzene requires less energy than producing them from raw materials. This leads to lower greenhouse gas emissions, helping to combat climate change.
"This initiative underscores CIL's commitment to collaboration and innovation in addressing our customers' most pressing challenges," said Cliff Caldwell, CEO of CIL. "By recovering and re-enriching depleted benzene-d6, we create a circular economy approach that is both economically and environmentally sustainable. As the world's largest supplier of benzene-d6, we are uniquely positioned to deliver this groundbreaking service."
CIL's benzene recovery program is the result of 12 months of dedicated development, expansion, and rigorous testing to ensure reliable capacity and uncompromising quality. CIL invites interested parties to inquire about the program's details and how to participate.
About Cambridge Isotope Laboratories, Inc.
CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.
Contact Information
Crissy Krisko
crissyk@isotope.com
1.978.269.1930
SOURCE: Cambridge Isotope Laboratories, Inc.
View the original press release on accesswire.com
Cambridge Isotope Laboratories, Inc.

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Ecological Threat Report 2025: Extreme Wet-Dry Seasons Emerge as Critical Conflict Catalyst29.10.2025 06:00:00 CET | Press release
Approximately 2 billion people - one quarter of humanity - now live in regions experiencing moderate to severe increases in seasonality LONDON, GB / ACCESS Newswire / October 29, 2025 / New research from the Institute for Economics & Peace reveals that changing rainfall patterns are significantly amplifying conflict risks worldwide. The 2025 Ecological Threat Report (ETR), released today, finds conflict death rates are substantially higher in areas where rainfall is concentrating into fewer months, compared to regions where rain is spreading more evenly throughout the year.Ecological Threat Report 2025 Analysing Ecological Threats, Resilience & Peace Key Findings On average in areas where wet and dry seasons are becoming more extreme, there are four times as many conflict deaths as areas where it has decreased. In 2024, natural hazards triggered 45 million short-term internal displacements across 163 countries, the highest figure since at least 2008. Western Brazil, including parts of
Karbon-X Celebrates Major Milestone in Senegal Mangrove Restoration Project28.10.2025 13:00:00 CET | Press release
Planting completed across 7,000 hectares in partnership with Woodside Energy, advancing community-led climate action. DAKAR, SN / ACCESS Newswire / October 28, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to announce a significant milestone in its ABC Mangrove Project, one of West Africa's largest community-led restoration initiatives with the successful completion of planting across more than 7,000 hectares of mangroves along Senegal's coastline. Developed through ALLCOT, Karbon-X's project development and advisory arm (ALLCOT-A Karbon-X Company), and in partnership with Woodside Energy, the project is helping restore critical blue-carbon ecosystems that protect biodiversity, strengthen local economies, and capture carbon naturally from the atmosphere. Through this multi-year effort, thousands of local community members have been engaged in the planting and care of mangroves, creating new jobs, skills training, and sustainable income opportunities for wome
Florence Healthcare Launches SiteLink on AWS Marketplace, Extending its Clinical Trial Operations Platform Capabilities to Cloud28.10.2025 13:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors and research sites worldwide, announced today that SiteLink, a key offering of Florence's Trial Operations Platform, is now available in AWS Marketplace. SiteLink accelerates study startup and enables real-time document distribution, monitoring, and data exchange with study sites, addressing the critical digital divide in clinical trials. With only 30% of global research sites currently using digital workflows, SiteLink helps bridge this gap by automating sponsor-site operational workflows. Bringing the Florence Trial Operations Platform Benefits to AWS As a core component of Florence's Trial Operations Platform, SiteLink delivers the same proven results that have made Florence the #1 clinical trial management solution for six consecutive years. The platform enables: Faster Startup: Up to 70% faster study activation timelines through automa
GoodData Brings AI-Native Data Intelligence to Financial Services28.10.2025 10:00:00 CET | Press release
Embeddable, compliant, and auditable AI agents unlock trusted automation for banks, insurers, and financial institutions. SAN FRANCISCO, CA / ACCESS Newswire / October 28, 2025 / GoodData, a leading analytics and data intelligence company, today unveiled new finance-focused applications for its composable AI platform, designed to tackle the industry's toughest challenges. By combining its AI Lake, AI Hub, and AI Apps into a single foundation for enterprise data intelligence, the next-generation platform gives financial institutions powerful tools to build and deploy AI agents. These agents can detect and investigate fraud in seconds with audit trails regulators can trust, keeping portfolios compliant in real time within industry guidelines. This streamlines regulatory reporting by compiling, checking, and submitting disclosures transparently, all while meeting strict standards for financial compliance, governance, and security. Purpose-built for finance The financial services sector fa
Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 202527.10.2025 14:00:00 CET | Press release
With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-D ISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom